drugset / Trial / NCT05979363
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia
Timeline
- Start
- 2023-08-14
- Primary completion
- 2026-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | anti-BCMA CAR-T | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | anti-BCMA CAR-T | Cell therapy | 4e+06 cells/kg | Intravenous |